AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16194199 — intervention group
Group type: COMPARATOR
Intervention: Facteur Willebrand-LFB
Number of subjects: 25
Study 12131732 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined magnetic field device (30-minute treatment per day for 9 months)
Number of subjects: 201
Study 12131732 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 201
Study 10655906 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (target plasma concentration of 0.3 ng ml‐1)
Number of subjects: 9
Study 10655906 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (target plasma concentration of 0.6 ng ml‐1)
Number of subjects: 9
Study 10655906 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study 8556173 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation therapy
Number of subjects: 164
Study 8556173 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy, non-anticoagulated persons)
Number of subjects: 164
Study 2097487 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 40
Study 2097487 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 40
Study 7353472 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of methamphetamine
Number of subjects: 18
Study 7353472 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of secobarbital
Number of subjects: 18
Study 7353472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31594077 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (3-5 MIU/m(2), once daily) in combination with lamivudine for 12 weeks; followed by lamivudine for 24 weeks after interferon discontinuation.
Number of subjects: 46
Study 31594077 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated children with immune-tolerant phase chronic hepatitis B).
Number of subjects: 46
Study 31594077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention in patients aged 1 to 7 years.
Number of subjects: 46
Study 31594077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention in patients aged 7 to 15 years.
Number of subjects: 46
Study 31594077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with normal baseline ALT levels.
Number of subjects: 46
Study 31594077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with abnormal baseline ALT levels.
Number of subjects: 46
Study 31594077 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HBsAg < 3,000 IU/ml at 24 weeks of treatment.
Number of subjects: 46
Study 31594077 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression analysis.
Number of subjects: 46
Study 27840148 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty with radial access, bivalirudin, thromboaspiration, drug-eluting stents
Number of subjects: 3576
Study 26427105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sancaijiangtang powders with pioglitazone hydrochloride three times daily
Number of subjects: 168
Study 26427105 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone hydrochloride alone
Number of subjects: 168
Study 24709931 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (3 modules of 1.5 hours each focusing on URIs, over-the-counter medications, and medication management)
Number of subjects: 154
Study 24709931 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 154
Study 24709931 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum (control)
Number of subjects: 154
Study 22256738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal airway
Number of subjects: 101
Study 22256738 — intervention group
Group type: COMPARATOR
Intervention: Oropharyngeal airway
Number of subjects: 101
Study 22256738 — intervention group
Group type: COMPARATOR
Intervention: Comparison between nasopharyngeal and oropharyngeal airway
Number of subjects: 101
Study 18398653 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion therapy
Number of subjects: 1880
Study 18398653 — intervention group
Group type: COMPARATOR
Intervention: Observation (standard care)
Number of subjects: 1880
Study 16890673 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenously every 3 months for 1 year)
Number of subjects: 120
Study 16890673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 15619132 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution containing 300 mg flecainide and 20 mg cisapride
Number of subjects: 54
Study 15619132 — intervention group
Group type: COMPARATOR
Intervention: Three tablets each containing 100 mg flecainide
Number of subjects: 54
Study 11561137 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (2.0 g twice a day) for 7 days
Number of subjects: 20
Study 11561137 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (1.0 g every 8 h) for 7 days
Number of subjects: 20
Study 8986960 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliad training
Number of subjects: 0
Study 8986960 — intervention group
Group type: COMPARATOR
Intervention: Prior nursing experience
Number of subjects: 0
Study 8424515 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 40
Study 8424515 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40
Study 8424515 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 3476732 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional methods (phonetic and swallowing methods)
Number of subjects: 40
Study 3476732 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG with biofeedback
Number of subjects: 40
Study 3476732 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional methods (with dentures)
Number of subjects: 40
Study 3476732 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG with biofeedback (with dentures)
Number of subjects: 40
Study 3476732 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional methods (without dentures)
Number of subjects: 40
Study 3476732 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG with biofeedback (without dentures)
Number of subjects: 40
Study 29477795 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (40, 50, or 60 mg twice daily for four of six weeks for up to four cycles)
Number of subjects: 354
Study 29477795 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine (1000 mg/m2 weekly for three of four weeks for up to six cycles)
Number of subjects: 354
Study 27027929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 200 μg/kg body weight single oral dose, repeated after one week.
Number of subjects: 200
Study 27027929 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl benzoate 20% cream.
Number of subjects: 200
Study 27027929 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin 2.5%‐5% lotion.
Number of subjects: 200
Study 27027929 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐10% sulfur ointment.
Number of subjects: 200
Study 24117183 — intervention group
Group type: EXPERIMENTAL
Intervention: Portobello mushroom powder (600 IU/d vitamin D2)
Number of subjects: 0
Study 24117183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22592092 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV+RAL (300 mg bid + 400 mg bid)
Number of subjects: 94
Study 22592092 — intervention group
Group type: COMPARATOR
Intervention: ATV/r+TDF/FTC (300 mg/100 mg qd + 300 mg/200 mg qd)
Number of subjects: 94
Study 22592092 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV+RAL
Number of subjects: 94
Study 22592092 — intervention group
Group type: COMPARATOR
Intervention: ATV/r+TDF/FTC
Number of subjects: 94
Study 21402600 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with SVR
Number of subjects: 236
Study 21402600 — intervention group
Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 236
Study 18458661 — intervention group
Group type: EXPERIMENTAL
Intervention: Gp IIb/IIIa inhibitors
Number of subjects: 5303
Study 18458661 — intervention group
Group type: EXPERIMENTAL
Intervention: Gp IIb/IIIa inhibitors in acute coronary syndromes
Number of subjects: 5303
Study 16730932 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkylpolyglucoside-based vehicles
Number of subjects: 0
Study 16730932 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacopoeial vehicle
Number of subjects: 0
Study 12756407 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension risk factors measured including urbanisation, obesity, plasma fibrinogen, lipids, insulin, serum gamma glutamyl‐transferase, dietary intake, smoking and alcohol consumption.
Number of subjects: 1657
Study 10933123 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus antibiotics
Number of subjects: 4
Study 8613045 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection into the lower esophageal sphincter
Number of subjects: 31
Study 8613045 — intervention group
Group type: EXPERIMENTAL
Intervention: Second injection of botulinum toxin
Number of subjects: 31
Study 1350540 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin gel induction of labor
Number of subjects: 108
Study 1350540 — intervention group
Group type: COMPARATOR
Intervention: Non-induced (continued without intervention)
Number of subjects: 108
Study 3891796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical scaling and root planing
Number of subjects: 15
Study 3891796 — intervention group
Group type: COMPARATOR
Intervention: Modified Widman flap procedure
Number of subjects: 15
Study 3891796 — intervention group
Group type: COMPARATOR
Intervention: Modified Kirkland flap procedure
Number of subjects: 15
Study 31450518 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based carer-assisted therapy
Number of subjects: 91
Study 31450518 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based therapist-delivered therapy
Number of subjects: 91
Study 29730659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levothyroxine treatment
Number of subjects: 1
Study 29730659 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration
Number of subjects: 1
Study 27175481 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon fistuloplasty
Number of subjects: 211
Study 27175481 — intervention group
Group type: COMPARATOR
Intervention: Plain balloon fistuloplasty
Number of subjects: 211
Study 24481581 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexketoprofen trometamol (DT) 50 mg
Number of subjects: 20
Study 24481581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24481581 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexketoprofen trometamol (DT)
Number of subjects: 20
Study 22041256 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive behavioral therapy (CBT)
Number of subjects: 0
Study 22041256 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (non-substance-using comparison group)
Number of subjects: 0
Study 20854630 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (4 to 16 mg once daily for 7 days)
Number of subjects: 2500
Study 20854630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study 17967672 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating catheter group (SC)
Number of subjects: 60
Study 17967672 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter group 1 (CC 1)
Number of subjects: 60
Study 17967672 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter group 2 (CC 2)
Number of subjects: 60
Study 17967672 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study 15057672 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 50
Study 15057672 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 50
Study 11434650 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral arginine (ARG) 9.0 g/d for 9 days, then 18.0 g/d for 9 more days in HD patients
Number of subjects: 30
Study 11434650 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral arginine (ARG) in crossover study
Number of subjects: 30
Study 11434650 — intervention group
Group type: COMPARATOR
Intervention: Oral arginine (ARG)
Number of subjects: 30
Study 11434650 — intervention group
Group type: COMPARATOR
Intervention: Canola oil (CanO) in addition to ARG
Number of subjects: 30
Study 11434650 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral arginine (ARG) (+/- CanO)
Number of subjects: 30
Study 9515999 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation starting on postoperative day 3
Number of subjects: 86
Study 9515999 — intervention group
Group type: COMPARATOR
Intervention: Inpatient rehabilitation starting on postoperative day 7
Number of subjects: 86
Study 7988127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (200 micrograms/min)
Number of subjects: 18
Study 7988127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (175 micrograms/min)
Number of subjects: 18
Study 7988127 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 18
Study 2605083 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive ACP (manual or electrical at 10 Hz for 5 min)
Number of subjects: 500
Study 2605083 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ACP (stimulation via a conducting stud or by pressure)
Number of subjects: 500
Study 2605083 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive ACP
Number of subjects: 500
Study 2605083 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetics (cyclizine 50 mg, metoclopramide 10 mg)
Number of subjects: 500
Study 2605083 — intervention group
Group type: COMPARATOR
Intervention: Dummy ACP point stimulation
Number of subjects: 500
Study 4856938 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% etidocaine with 1:200,000 epinephrine
Number of subjects: 50
Study 4856938 — intervention group
Group type: COMPARATOR
Intervention: 1% etidocaine without epinephrine (plain solution)
Number of subjects: 50
Study 4856938 — intervention group
Group type: COMPARATOR
Intervention: 0.5% etidocaine for bilateral intercostal nerve block (plain solution)
Number of subjects: 50
Study 30059196 — intervention group
Group type: EXPERIMENTAL
Intervention: ALKS 3831 (10 mg OLZ/10 mg SAM)
Number of subjects: 48
Study 30059196 — intervention group
Group type: EXPERIMENTAL
Intervention: OLZ (10 mg OLZ)
Number of subjects: 48
Study 30059196 — intervention group
Group type: EXPERIMENTAL
Intervention: B-OLZ (10 mg B-OLZ)
Number of subjects: 48
Study 28115072 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 169
Study 28115072 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 169
Study 28115072 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 169
Study 26632742 — intervention group
Group type: EXPERIMENTAL
Intervention: Early statin use
Number of subjects: 719
Study 26632742 — intervention group
Group type: COMPARATOR
Intervention: No early statin use
Number of subjects: 719
Study 23111141 — intervention group
Group type: COMPARATOR
Intervention: Excluded patients
Number of subjects: 318
Study 20931218 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric wrist extension training (30 repetitions at 70% MVC for 8 weeks, 5 times a week)
Number of subjects: 13
Study 20931218 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric wrist extension training
Number of subjects: 13
Study 19002741 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mm stapler size
Number of subjects: 200
Study 19002741 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mm stapler size
Number of subjects: 200
Study 19002741 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 200
Study 16614127 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine (approximately 600 microg/d)
Number of subjects: 0
Study 16614127 — intervention group
Group type: EXPERIMENTAL
Intervention: High-selenium yeast (approximately 600 microg/d)
Number of subjects: 0
Study 16614127 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite (approximately 600 microg/d)
Number of subjects: 0
Study 16614127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16244429 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sugar chocolate containing polydextrose and lactitol
Number of subjects: 0
Study 16244429 — intervention group
Group type: COMPARATOR
Intervention: Regular chocolate (control)
Number of subjects: 0
Study 11906540 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate awareness (being folate aware)
Number of subjects: 2431
Study 11906540 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeing folate promotional material
Number of subjects: 2431
Study 11906540 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview about folate and NTDs
Number of subjects: 2431
Study 11906540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy status
Number of subjects: 2431
Study 10441781 — intervention group
Group type: EXPERIMENTAL
Intervention: GBE 150 mg (50 mg t.d.s)
Number of subjects: 31
Study 10441781 — intervention group
Group type: EXPERIMENTAL
Intervention: GBE 300 mg (100 mg t.d.s.)
Number of subjects: 31
Study 10441781 — intervention group
Group type: EXPERIMENTAL
Intervention: GBE 120 mg mane
Number of subjects: 31
Study 10441781 — intervention group
Group type: EXPERIMENTAL
Intervention: GBE 240 mg mane
Number of subjects: 31
Study 10441781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 7558104 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy
Number of subjects: 0
Study 7558104 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 0
Study 7558104 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 0
Study 7558104 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 7558104 — intervention group
Group type: COMPARATOR
Intervention: Prevention of relapse therapy
Number of subjects: 0
Study 2193776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 0
Study 2193776 — intervention group
Group type: COMPARATOR
Intervention: Conventional guidance
Number of subjects: 0
Study 402663 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0
Study 402663 — intervention group
Group type: EXPERIMENTAL
Intervention: l-amphetamine
Number of subjects: 0
Study 402663 — intervention group
Group type: EXPERIMENTAL
Intervention: lithium
Number of subjects: 0
Study 402663 — intervention group
Group type: EXPERIMENTAL
Intervention: d- and l-amphetamine combined with lithium
Number of subjects: 0
Study 402663 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 31849036 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-based cervical cancer screening through community health campaigns (CHCs)
Number of subjects: 0
Study 31652688 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based self-management intervention
Number of subjects: 464
Study 31652688 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 464
Study 28627861 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic ai chi training program (N=15 patients)
Number of subjects: 30
Study 28627861 — intervention group
Group type: COMPARATOR
Intervention: Control group (dry land therapy, N=15 patients)
Number of subjects: 30
Study 25374288 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum depressive symptoms (EPDS ≥10)
Number of subjects: 0
Study 23922400 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-style physical activity intervention (n = 44)
Number of subjects: 89
Study 23922400 — intervention group
Group type: COMPARATOR
Intervention: Control group (advisory leaflet; n = 45)
Number of subjects: 89
Study 21334498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) intervention on PDAs for 4 weeks
Number of subjects: 75
Study 21334498 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 75
Study 19838891 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of correct information to incorrect responses
Number of subjects: 696
Study 19838891 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 696
Study 17213752 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI)
Number of subjects: 61
Study 17213752 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (EX)
Number of subjects: 61
Study 17213752 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither SPI nor EX
Number of subjects: 61
Study 14732659 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% wt/vol aminolevulinic acid hydrochloride (ALA) followed by photodynamic therapy (PDT)
Number of subjects: 243
Study 14732659 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 243
Study 11573023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for depression and low social support
Number of subjects: 2481
Study 11573023 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2481
Study 9589833 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 50 mg orally + Misoprostol 800 micrograms vaginally
Number of subjects: 300
Study 9589833 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol given 3, 4, or 5 days after methotrexate
Number of subjects: 300
Study 9589833 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and Misoprostol
Number of subjects: 300
Study 9589833 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 300
Study 9589833 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 300
Study 7923645 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin (0.6 mg/kg bolus and 0.2 mg/kg per hour infusion without aPTT adjustment)
Number of subjects: 2564
Study 7923645 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5000-U bolus and 1000-1300-U/h infusion, adjusted to APTT of 60 to 90 seconds)
Number of subjects: 2564
Study 7923645 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy with Heparin
Number of subjects: 2564